Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR). Study aims to help tailor patients' treatments and improve outcomes by: \[i\] studying imaging biomarkers of PVR, and \[ii\] develop AI models for PVR detection. Inclusion: * Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1. * Patients with 'simple' retinal detachment without PVR recruited to a PhD study. Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
To study multimodal imaging biomarkers of PVR.
Timeframe: Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.